Synopsis Almost 75% of individuals with tuberous sclerosis complex (TCS) have Facial angiofibromas which results in disfigurement and morbidity. Current treatment options are partially effective, produce scarring and repetitively occur. Thus, the aim of our present study was to evaluate the safety and efficacy of topical rapamycin for TSC-related facial angiofibromas. This week’s “ MED FACT” discusses a clinical trial from JAMA Dermatology, “Efficacy and Safety of Topical Rapamycin in Patients with Facial Angiofibromas Secondary to Tuberous Sclerosis Complex”.
Authors: Mary Kay Koeniget. al. Key Takeaways: The preferred dose of 1%rapamycin was used to treat TSC-related facial angiofibromas Objective: The objective of this study was to evaluate the safety and efficacy of topical rapamycin for TSC-related facial angiofibromas Study Type: Randomized Clinical Trial Participants: 179 What…
